We have experimentally probed that HMGB1, HMGB2 and two of their partners, MIEN1 and NOP53 are also involved in the response of ovarian cancer cells to several drugs used in chemotherapy against EOC. This evidence concerns the gene HMGB2 and ovarian carcinoma.